LUM015

Small molecule

LLumicell, Inc.

LUM015 is one of 67 small molecule programs targeting Intestinal Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal CancerActive, not recruiting

Breast CancerActive, not recruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Avastin

Zolymbus

1 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

Acupan

YYonsei University

Preclinical

1 5

Chantix

PPrism Pharmaceuticals

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 10

Bisphosphonate

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Intestinal Cancer

NCT02584244

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Feasibility Study of Intraoperative Imaging in Breast Cancer

Completed·LLumicell, Inc.·Phase 1/2·NCT02438358·60 enrolled

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

Terminated·LLumicell, Inc.·Phase 2·NCT04440982·98 enrolled

Intestinal Cancer1 trial

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

Recruiting·LLumicell, Inc.·Phase 1/2·NCT02584244·66 enrolled

Unspecified1 trial

Cathepsin Activatable Fluorescent Probe

Completed·DDavid Kirsch·Phase 1·NCT01626066·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for LUM015. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LUM015 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LUM015. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lumicell, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: LLumicell, Inc.

LUM015

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Breast Cancer2 trials

Intestinal Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News